908 Devices (NASDAQ:MASS – Get Free Report) and Nuwellis (NASDAQ:NUWE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.
Earnings and Valuation
This table compares 908 Devices and Nuwellis”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 908 Devices | $56.20 million | 5.43 | $19.49 million | ($1.00) | -8.07 |
| Nuwellis | $8.27 million | 0.03 | -$17.52 million | ($2,238.46) | -0.00 |
Insider and Institutional Ownership
88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by insiders. Comparatively, 1.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares 908 Devices and Nuwellis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 908 Devices | -62.40% | -14.03% | -10.40% |
| Nuwellis | -214.90% | -32,351.83% | -249.08% |
Analyst Ratings
This is a summary of recent recommendations and price targets for 908 Devices and Nuwellis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 908 Devices | 1 | 0 | 1 | 0 | 2.00 |
| Nuwellis | 1 | 0 | 0 | 0 | 1.00 |
908 Devices presently has a consensus target price of $12.00, suggesting a potential upside of 48.70%. Given 908 Devices’ stronger consensus rating and higher probable upside, equities analysts plainly believe 908 Devices is more favorable than Nuwellis.
Volatility and Risk
908 Devices has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.
Summary
908 Devices beats Nuwellis on 13 of the 14 factors compared between the two stocks.
About 908 Devices
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
About Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.
